Your browser doesn't support javascript.
loading
ConquerFear-Group: A randomized controlled trial of an online-delivered group-based psychological intervention for fear of cancer recurrence in breast cancer survivors.
Tauber, Nina M; O'Toole, Mia S; Jensen, Anders B; Butow, Phyllis N; Thewes, Belinda; Elkjaer, Emma; Knutzen, Sofie; von Heymann, Annika; Johansen, Christoffer; Zachariae, Robert.
Afiliação
  • Tauber NM; Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark.
  • O'Toole MS; Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark.
  • Jensen AB; Department of Oncology, Aarhus University Hospital, Aarhus, Denmark.
  • Butow PN; Danish Breast Cancer Group Center for Late Effects (DCCL), Aarhus, Denmark.
  • Thewes B; School of Psychology, University of Sydney, Sydney, New South Wales, Australia.
  • Elkjaer E; School of Psychology, University of Sydney, Sydney, New South Wales, Australia.
  • Knutzen S; Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark.
  • von Heymann A; Department of Psychology and Behavioural Sciences, Aarhus University, Aarhus, Denmark.
  • Johansen C; Cancer Survivorship and Treatment Late Effects (CASTLE), Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
  • Zachariae R; Cancer Survivorship and Treatment Late Effects (CASTLE), Department of Oncology, Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark.
Psychooncology ; 32(9): 1424-1432, 2023 09.
Article em En | MEDLINE | ID: mdl-37489745
ABSTRACT

OBJECTIVE:

Fear of cancer recurrence (FCR) is a distressing concern among cancer survivors. Interventions to address FCR need to be effective but also accessible and low cost. This randomized controlled trial evaluated the efficacy of an online group-based psychological intervention for FCR (ConquerFear-Group).

METHODS:

Eligible breast cancer (BC) survivors had completed primary treatment 3 months-5 years previously, were ≥18 years, and scored ≥22 on the Fear of Cancer Recurrence Inventory-Short Form (FCRI-SF). Participants were randomized to online ConquerFear-Group (focusing on metacognitive strategies, values-clarification, and education about follow-up behavior) or online group-based relaxation training (active control). Questionnaires were completed at baseline (T1), 1 week post-intervention (T2), three (T3) and six (T4) months later. The primary outcome was FCR (FCRI total). A number of secondary and process outcomes were also collected. Treatment effects were evaluated with mixed linear models.

RESULTS:

Of 866 eligible BC survivors, 475 (55%) completed the FCR screening, and 85 (18%) were randomized to ConquerFear-Group or relaxation training (2 × 6 groups). Compared with control participants, ConquerFear-Group participants experienced larger reductions in FCR (Cohen's d = 0.47, p = 0.001) and FCR severity (d = 0.57, p < 0.001), as well as mindfulness and decentering from baseline through follow-up, and improvements in emotion regulation (T2), worry (T2, T3) and rumination (T2) at some time points.

CONCLUSIONS:

The results demonstrated statistically significant and stable effects of ConquerFear-Group on FCR that were maintained over a 6-month period. It is suggested to investigate the program in a real-life setting, where a pragmatic trial can further demonstrate feasibility and effectiveness.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Transtornos Fóbicos / Neoplasias da Mama / Sobreviventes de Câncer Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans Idioma: En Revista: Psychooncology Ano de publicação: 2023 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Contexto em Saúde: 1_ASSA2030 / 2_ODS3 Base de dados: MEDLINE Assunto principal: Transtornos Fóbicos / Neoplasias da Mama / Sobreviventes de Câncer Tipo de estudo: Clinical_trials / Prognostic_studies Limite: Female / Humans Idioma: En Revista: Psychooncology Ano de publicação: 2023 Tipo de documento: Article